Notice Concerning the Launch of GMP Master Cell Bank (MCB) Manufacturing Services for Clinical iPSCs

-Providing an End-to-End Workflow Spanning the Manufacturing, Gene Editing, and MCB Manufacturing of Clinical iPSCs-

March 2, 2026

REPROCELL Inc. (the "Company") hereby announces that it has launched a Master Cell Bank (MCB) manufacturing service for clinical iPSCs. The MCB serves as the starting material for the final cell product and is extremely important from the perspectives of ensuring consistent quality and regulatory compliance. This service will be provided at the GMP manufacturing facility of our wholly-owned subsidiary, REPROCELL USA Inc.

With this new service, the Company has established a system capable of providing a series of workflows related to clinical iPSCs—namely, "Donor Screening," "StemRNA™ Clinical Seed iPSC Manufacturing," "StemEdit Clinical Gene Editing," and "GMP Cell Banking"—within an integrated framework. This enables cell therapy development companies to reduce uncertainties in regulatory requirements and manufacturing processes, and to construct a more rational and viable development roadmap.

Concurrently, the Company will also begin sales of MCBs manufactured using the "StemRNA™ Clinical iPSC Seed Clone – LLF-34-F3," a clinical iPSC supported by an active FDA Drug Master File (DMF).

The key highlights of each workflow related to clinical iPSC manufacturing provided by the Company are as follows:

StemRNA™ Clinical iPSC Seed Clone

- Strict Donor Sourcing and Eligibility: Utilizes donor materials that meet the requirements of the FDA, EMA (Europe), and PMDA (Japan), with appropriate consent obtained for therapeutic use.
- Proprietary RNA Reprogramming Technology: The "StemRNA™ Clinical iPSC Seed Clone," generated using the Company's proprietary technology, is supported by an active FDA DMF. Utilizing our seed clone, Gameto Inc. has obtained FDA IND clearance and initiated Phase III clinical trials.

StemEdit Clinical Gene Editing

- Highly Efficient and Low Off-Target Editing Design: Based on Profluent's "OpenCRISPR-1™," this design is engineered for high on-target efficiency with reduced off-target activity and lower predicted immunogenicity.
- GMP-Compliant Workflow: Utilizing the Company's StemRNA™ Clinical iPSC Seed Clone, we support a smooth transition from the research stage to clinical application and commercial

production.

- Reduction of Commercial Risk: Provides an alternative to conventional CRISPR technologies that involve complex licensing issues, thereby contributing to the mitigation of commercial risks in cell therapy drug development.

GMP Master Cell Bank (MCB) Manufacturing Services

- GMP-Compliant Manufacturing in the U.S.: MCB manufacturing in compliance with FDA standards is conducted at the GMP facility of REPROCELL USA Inc.
- Support for Manufacturing Under European Regulations: MCB/WCB manufacturing at an AEMPS-certified facility under European Medicines Agency (EMA) oversight is also possible through our partner company, Histocell (Spain).

The impact of this matter on the Company's financial results is expected to be minimal; however, if it becomes clear that there will be a material impact on financial results depending on the specific progress of sales in the future, the Company will promptly announce such information.